CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value

Cancer Investigation

Volumn 27, Issue 7, 2009, Pages 788-793

  Liang, Yu Xiang ^a   He, Hui Chan ^a   Han, Zhao Dong ^a   Bi, Xue Cheng ^b   Dai, Qi Shan ^a   Ye, Yong Kang ^a   Qin, Wei Jun ^c   Zeng, Guo Hua ^d   Zhu, Gang ^e   Xu, Chuan Liang ^f   Zhong, Wei De ^a  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

^e BEIJING HOSPITAL   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced renal cell carcinoma; CD147; Clinical pathology; Prognosis; VEGF

Indexed keywords

CD147 ANTIGEN; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER SURVIVAL; FEMALE; HEPATOSPLENOMEGALY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL RATE;

AGED; ANTIGENS, CD147; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68849132734     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802709167     Document Type: Article

References (26)

1. Eble, J.N.; Sauter, G.; Epstein, J.I.; Sesterhenn, I.A. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, France: IARC Press, 2004, 10-34.
2. WenChiuan, T.; LaiFa, S.; Shin, N. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol 2007, 25, 73-80.
3. Peter, J.; Van, V.; James, R. A phase-II study of flavopiridol in patients with advanced renal cell carcinoma: results of southwest oncology group trial 0109. Cancer Chemother Pharmacol 2005, 56, 39-45. (Pubitemid 41201754)
4. Herman, J.G.; Latif, F.; Weng, Y. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994, 91, 9700-9704. (Pubitemid 24311875)
5. Clifford, S.C.; Prowse, A.H.; Affara, N.A.; Buys, C.H.; Maher, E.R. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998, 22, 200-209.
6. Kondo, K.; Yao, M.; Yoshida, M. Comprehensive mutational analysis of theVHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002, 34, 58-68. (Pubitemid 34260597)
7. Sun, J.; Hemler, M.E. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001, 61, 2276-2281.
8. Sameshima, T.; Nabeshima, K.; Toole, B.P. Expression of emmprin (CD147); a cell surface inducer of matrix metalloproteinases in normal human brain and gliomas. Int J Cancer 2000, 88, 21-27.
9. Kanekura, T.; Chen, X.; Kanzaki, T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002, 99, 520-528.
10. Ranuncolo, S.M.; Armanasco, E.; Cresta, C. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003, 106, 745-751. (Pubitemid 36993399)
11. Sienel, W.; Hellers, J.; Morresi-Hauf, A. Prognostic impact ofmatrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003, 103, 647-651. (Pubitemid 36091469)
12. Nabeshima, K.; Iwasaki, H.; Koga, K.; Hojo, H.; Suzumiya, J.; Kikuchi, M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006, 56, 359-367.
13. Rini, Brian, I.; RathmellW.K. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res 2007, 13, 741s-746s.
14. Qing, Z.; Xinguo, C.; Jun, Z. CD147, MMP-2, MMP-9 and MVDCD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 2006, 5, 808-814. (Pubitemid 44775139)
15. Kaelin Jr., W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10, 6290S-6295S.
16. Yoshio, I.; Tomoe, M.; Mikio, N.; Yutaka, S.; Nobuo, O.; Nobuyoshi, H.; Koji, N.; Katsuhiko, Y.; Kyosuke, Y.; Kiyoshi, O.; Makio, K.; Mitsuyoshi, U. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 2004, 101, 1994-2000.
17. Sabine, R.; Natalie, R.; Volker, A. High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006, 119, 1800-1810. (Pubitemid 44356836)
18. Jianxin, S.; Hemler, Martin E. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001, 61, 2276-2281.
19. Tang, Y.; Nakada, M.T.; Rafferty, P. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 2006, 4, 371-377. (Pubitemid 44035156)
20. Liang, Q.; Xiong, H.; Gao, G. Inhibition of basigin expression in glioblastoma cell line via antisense RNA reduces tumor cell invasion and angiogenesis. Cancer Biol Ther 2005, 4, 759-762. (Pubitemid 41351176)
21. Ferrara, N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9, 2-10. (Pubitemid 38747842)
22. Willett, C.G.; Boucher, Y.; di Tomaso, E. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10, 145-147.
23. Stanley, Z.; Michelle, H.; Ellen E.R. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Path 2001, 158, 1921-1928. (Pubitemid 32545174)
24. Gabison, E.E.; Mourah, S.; Steinfels, E.; Yan, L.; Hoang-Xuan, T.; Watsky, M.A.; De Wever, B.; Calvo, F.; Mauviel, A.; Menashi, S. DiVerential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epitheliostromal interactions and matrix metalloproteinase induction. Am J Pathol 2005, 166, 209-219. (Pubitemid 40051673)
25. Jin, J.S.; Hsieh, D.S.; Lin, Y.F.; Wang, J.Y.; Sheu, L.F.; Lee, W.H. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 2006, 13, 573-580. (Pubitemid 43760423)
26. Brian, I. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007, 13, 1098-1106.